1988
DOI: 10.1016/0092-8674(88)90060-8
|View full text |Cite
|
Sign up to set email alerts
|

cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
201
1
2

Year Published

1989
1989
2015
2015

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 520 publications
(206 citation statements)
references
References 47 publications
2
201
1
2
Order By: Relevance
“…Interestingly, the conversion of Sp histones to their modified form in vivo takes place in eggs treated with DMAP, indicating that the sperm histone kinase is DMAPinsensitive (41). The sperm histone kinase is thus likely to be distinct from the mitotic histone kinase p34 cdc2 (44) and from PKC, which are both inhibited by DMAP (45) (this study).…”
Section: Pkc-mediated Interphase Laminmentioning
confidence: 96%
“…Interestingly, the conversion of Sp histones to their modified form in vivo takes place in eggs treated with DMAP, indicating that the sperm histone kinase is DMAPinsensitive (41). The sperm histone kinase is thus likely to be distinct from the mitotic histone kinase p34 cdc2 (44) and from PKC, which are both inhibited by DMAP (45) (this study).…”
Section: Pkc-mediated Interphase Laminmentioning
confidence: 96%
“…It is constituted in part by a protein of 34 kDa, which shares H1 kinase activity and is related to the product of the gene cdc2 controlling the cell division in the yeast, Schizosaccharomyces pombe [2][3][4][5].…”
Section: Introductionmentioning
confidence: 99%
“…Des études ont montré que CDK1, -2, -5, -7 et -9 sont les protéine kinases les plus sensibles à la molécule [8]. Ainsi, exploitée par la société Cyclacel (Berkeley Heights, New Jersey, États-Unis) sous le nom de Seliciclib ou CYC202, elle a notamment atteint la phase 2 d'études cliniques pour le traitement du cancer du poumon non à petites cellules et, plus récemment, de la maladie de Cushing, dont les résultats sont attendus en 2017 4 . La rosco-2 L'article décrivant son activité inhibitrice est cité plus de 875 fois (source Web of Sciences TM ).…”
Section: Synthèse Revuesunclassified
“…3 L'estimation des cibles affectées par l'inhibiteur a été la plus exhaustive possible. 4 www.clinicaltrial.gov, NCT00372073 et NCT02160730. significatives d'enzymes natives, rendant ainsi possibles des approches à grande échelle, telles que le criblage moléculaire [5].…”
Section: Synthèse Revuesunclassified